RxDoctor Payments Data

Shuja Yousuf, MD

Internal Medicine · Brandon, MSNPI 1881643088

Payments from drug & device makers

$6,081in general payments, 2019–2025

Across 198 payments — averaging $30.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Enterra Medical, Inc.$2K
  • Johnson & Johnson$810
  • AbbVie$758
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$735
  • QOL Medical, LLC$317
  • Nestle Healthcare Nutrition Inc.$191
  • plus $970 from 13 others

What the payments were for

  • Travel & lodging$1,63527%
  • Food & beverage$4,31171%
  • Education$1352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,081 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$59,331
Medicare patients
127
Services billed
1,964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab16$417,955
LinzessLinaclotide28$34,406
ClenpiqSod Picosulf/Mag Ox/Citric Ac25$4,178
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C15$2,224
CholestyramineCholestyramine (With Sugar)21$1,390
Pantoprazole Sodium105$1,226
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl60$947
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg34$934
Famotidine36$572
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl34$549
Sucralfate16$501
Dicyclomine Hcl11$459
Omeprazole11$77
Metronidazole12$73

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$810$417,95516 claims
AbbVieLinzess$758$34,40628 claims
Ferring Pharmaceuticals Inc.Clenpiq$50$4,17825 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$735$2,22415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Brandon

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →